Abstract 2124
Background
To explore the differences of MRI scan between pituitary adenomas and craniopharyngioma from MR image features to 3D based texture features.
Methods
A total number of 131 patients were introduced into this study (pituitary Adenomas =68; craniopharyngioma=63) with pre-surgery MRI image. Qualitative MR features and MRI texture features of lesion were evaluated using chi-square tests, Fisher exact test or Mann-Whitney U test. Multivariate logistic regression analyses were performed to access their ability as independent predictors. Accuracy measures were calculated substantially for the significant features.
Results
Five MRI features were suggested to be significantly different between pituitary adenomas and craniopharyngioma and one of them, cystic alteration could be considered as independent practical predictors. Three texture features from contrast enhanced images (Histo-Skewness, GLCM-Contrast and GLCM-Energy), two texture features from T2WI (Histo-Skewness and GLCM-Contrast) were found to be significantly related to discrimination between two types of diseases. Two texture features (Histo-Skewness and GLCM-Contrast) were found significantly to be in relation with cystic alteration.
Conclusions
Both of MRI image features and texture features, could make significant discrimination between pituitary adenoma and craniopharyngioma and represent practical diagnostic value; in addition, two type features associate with each other.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xuelei Ma.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3034 - Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL STUDY
Presenter: Maria Agnese Fabbri
Session: Poster Display session 2
Resources:
Abstract
4772 - Real world comparison of the impact of adjuvant capecitabine in women with high-risk triple-negative breast cancer after neoadjuvant chemotherapy
Presenter: Maysa Vilbert
Session: Poster Display session 2
Resources:
Abstract
5627 - Influence of age on the indication of adjuvant chemotherapy in early breast cancer using Oncotype DX. An analysis of 240 patients treated in the Institut Catala d’Oncologia (ICO) hospitals
Presenter: Sabela Recalde
Session: Poster Display session 2
Resources:
Abstract
3917 - Impact of delayed neoadjuvant systemic chemotherapy on survival among breast cancer patients
Presenter: Mariana Chavez Mac Gregor
Session: Poster Display session 2
Resources:
Abstract
2246 - Clinical Confirmation of Higher Exposure to Niraparib in Tumor vs Plasma in Patients With Breast Cancer
Presenter: Laura Spring
Session: Poster Display session 2
Resources:
Abstract
581 - The rationale for the effectiveness of systemic treatment of breast cancer depending on the body weight index
Presenter: Mohammad Hojouj
Session: Poster Display session 2
Resources:
Abstract
5327 - Response to neoadjuvant chemotherapy in HER2 non-overexpressing breast cancer subtypes
Presenter: Silvia Mihaela Ilie
Session: Poster Display session 2
Resources:
Abstract
3613 - Pre-specified interim analysis of the SAFE trial (NCT2236806): a 4-arm randomized, double-blind, controlled study evaluating the efficacy and safety of cardiotoxicity prevention in non-metastatic breast cancer patients treated with anthracyclines with or without trastuzumab.
Presenter: Lorenzo Livi
Session: Poster Display session 2
Resources:
Abstract
3736 - Safety of hypofractionated whole breast irradiation after conservative surgery for patients aged less than 60 years: a multi-center comparative study.
Presenter: Icro Meattini
Session: Poster Display session 2
Resources:
Abstract
5085 - Usefulness of NT-ProBNP as a biomarker of cardiotoxicity in breast cancer patients treated with trastuzumab
Presenter: Isabel Blancas López-Barajas
Session: Poster Display session 2
Resources:
Abstract